Drug notes:
MBX 1416 Clin1 post-bariatric hypoglycemia; MBX 4291 Clin0 obesity; undisclosed programs RD rare diseases, undisclosed
About:
MBX Biosciences is a clinical-stage biopharmaceutical company pioneering the development of Precision Endocrine Peptides (PEP™) for endocrine and metabolic disorders. Their innovative approach focuses on engineering peptides to improve their drug-like properties, enabling more effective and convenient treatments. MBX Biosciences is developing treatments for conditions such as hypoparathyroidism and post-bariatric hypoglycemia. They are also exploring the potential of their PEP™ platform for treating metabolic disorders. Their lead product, MBX 2109, a long-acting parathyroid hormone (PTH) analog being developed for the treatment of chronic hypoparathyroidism. It is currently in Phase 2 clinical trials. MBX Biosciences' innovative approach offers several advantages.
Quality Systems & Compliance SpecialistQuality Systems & Compliance S... Burlington, MA|8 days ago
Regulatory Affairs FellowRegulatory Affairs Fellow Burlington, MA|8 days ago
Senior Clinical Trial ManagerSenior Clinical Trial Manager Burlington, MA|8 days ago
Director, Contracts CounselDirector, Contracts Counsel Burlington, MA|18 days ago
Senior Director, Medical WritingSenior Director, Medical Writi... Burlington, MA|36 days ago
Clinical ScientistClinical Scientist Burlington, MA|42 days ago
Vice President, Global Commercial Asset LeadVice President, Global Commerc... United States|100+ days ago
Senior Director, Medical AffairsSenior Director, Medical Affai... Burlington, MA|Posting date unknown
Director, BioanalyticalDirector, Bioanalytical Burlington, MA|Posting date unknown
Associate Director, Statistical ProgrammingAssociate Director, Statistica... Burlington, MA|Posting date unknown
Senior Manager, Clinical Data ManagementSenior Manager, Clinical Data ... Burlington, MA|Posting date unknown
Senior Scientist, Drug SubstanceSenior Scientist, Drug Substan... Burlington, MA|Posting date unknown